Methylphenidate Transdermal System in Attention-Deficit Hyperactivity Disorder in Children: Profile Report1

Abstract

Attention-deficit hyperactivity disorder (ADHD) is estimated to affect ≈8–10% of school-age children. [4] Stimulant medication such as methylphenidate is commonly prescribed to treat ADHD. However, immediate-release oral formulations of methylphenidate may require multiple daily doses, which can cause problems and embarrassment for children at school. Extended- or sustainedrelease oral formulations may not cover the entire school day before the effects of the drug wear off and problems associated with administration of the tablets or capsules may occur. [5,6] The methylphenidate transdermal system (MTS) [Daytrana™] 2 is a method of delivering methylphenidate to the systemic circulation via absorption of the drug through the skin and it may also benefit some children who have difficulty swallowing tablets or capsules. [7] The features and properties of MTS are presented in table I. The patch, a combination of a multipolymeric adhesive matrix and methylphenidate, allows continuous release of methylphenidate throughout the day. [7] methylphenidate is a CNS agent thought to act on dopamine and noradrenaline (norepinephrine) pathways and thereby blocks the reuptake of these neurotransmitters into the presynaptic neuron. [8,9] In children with ADHD, MTS patches releasing methylphenidate doses of 10–30mg over a